Physician profile
Sandy Witzling
NPI 1972539179
$12,069.05
in general payments reported to CMS, 2019-2025
30 companies · $628 in 2025
The $628 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,928 · 2020: $1,818 · 2021: $2,877 · 2022: $1,578 · 2023: $1,772 · 2024: $1,467 · 2025: $628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,867.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $4,429.21 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $1,182.93 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $948.64 | 2019-2024 | Xarelto |
| Glaxosmithkline, LLC. | $784.89 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $694.33 | 2019-2024 | Prolia, Evenity |
| Novo Nordisk INC | $637.34 | 2019-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $559.37 | 2019-2025 | Verquvo, Gardasil 9, Capvaxive |
| Novartis Pharmaceuticals Corporation | $449.58 | 2019-2024 | |
| Amarin Pharma, INC. | $430.17 | 2019-2020 | |
| Lilly USA, LLC | $337.92 | 2019-2025 | Jardiance |
| Allergan, INC. | $275.01 | 2020 | |
| Phathom Pharmaceuticals, INC. | $213.97 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $203.61 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $114.87 | 2019-2020 | |
| Abbvie INC. | $113.59 | 2021-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $110.61 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $95.80 | 2024-2025 | Gemtesa |
| Esperion Therapeutics, INC. | $92.17 | 2021 | |
| Dexcom, INC. | $76.77 | 2022-2023 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.63 | 2025 | Jardiance |
| Insmed, INC. | $44.36 | 2024 | Arikayce |
| E.R. Squibb & Sons, L.L.C. | $33.22 | 2022-2023 | |
| Arbor Pharmaceuticals, INC. | $31.40 | 2021 | |
| Cequr Corporation | $29.46 | 2022 | |
| Ardelyx, INC. | $27.12 | 2025 | Ibsrela |
| Xeris Pharmaceuticals, INC. | $24.99 | 2023 | Gvoke Hypopen |
| Hikma Pharmaceuticals USA | $21.82 | 2021 | |
| Eyevance Pharmaceuticals LLC | $21.82 | 2021 | |
| Sunovion Pharmaceuticals INC. | $18.01 | 2020 | |
| Cvrx, INC. | $14.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandy Witzling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.